Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis

Abstract

Background

There are few reviews comparing the long-term outcomes of the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in a hypertensive population because both are effective in reducing blood pressure. None of them compared angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers with a placebo group in patients with essential hypertension, because few studies exist with this design.

Methods

A systematic search of PUBMED, LILACS, SCIELO, ICTRP, Cochrane, EMBASE and ClinicalTrials.gov from 1 January 2000 until 31 December 2015 selected prospective studies that reported an association between the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in the following cardiovascular outcomes: heart failure/hospitalisation, stroke, acute myocardial infarction, total cardiovascular deaths, total deaths and total outcomes. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were combined by using a fixed-effects model.

Results

Seventeen studies (n = 73,761) were included of which 12 studies were randomly assigned to angiotensin II receptor blocker therapy (n = 24,697) and five to angiotensin-converting enzyme inhibitors (n = 12,170). Angiotensin-converting enzyme inhibitors proved to be significant in reducing total deaths (OR 0.85, 95% CI 0.78–0.93) and cardiovascular deaths (OR 0.77, 95% CI 0.69–0.87). Angiotensin II receptor blocker therapy did not show a reduction in total deaths (OR 1.02, 95% CI 0.96–1.09) or cardiovascular deaths (OR 0.95, 95% CI 0.86–1.06). For acute myocardial infarction, stroke and heart failure/hospitalisation, the reductions were significant for both classes.

Conclusion

Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use is similar in preventing major cardiovascular outcomes regarding acute myocardial infarction, stroke and heart failure/hospitalisation. However, the use of angiotensin-converting enzyme inhibitors is more effective in reducing total deaths and cardiovascular deaths than angiotensin II receptor blockers.

Keywords

Meta-analysis hypertension outcomes angiotensin-converting enzyme inhibitor angiotensin II receptor blocker

Get full access to this article

View all access options for this article.

References

Kornelia

Dirk

Guy

et al.

Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prevent Cardiol 2016; 23: 1–96.

Wang

Lee

Fabsitz

et al.

A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the Strong Heart Study. Hypertens Am Heart Assoc 2006; 47: 403–409.

Montalescot

. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949–3003.

Padwal

. Evidence based management of hypertension: cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001; 322: 977–980.

Evora

PRB

Nather

Rodrigues

. Prevalence of heart disease demonstrated in 60 years of the Arquivos Brasileiros de Cardiologia. Arq Bras Cardiol 2014; 102: 3–9.

Word Health Organization. Cardiovascular diseases (CVDs) Fact Sheet. WHO. www.who.int/mediacentre/factsheets/fs317/en/ (2012, accessed 21 January 2015).

Santulli

. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis 2013; 1: 1–2.

Chobanian

AAV

Bakris

GLG

Black

HHR

et al.

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

Katakam

Brukamp

Townsend

. What is the proper workup of a patient with hypertension? Cleveland Clin J Med 2008; 75: 663–672.

10.

Institute for Clinical Systems Improvement (ICSI). Hypertension diagnosis and treatment. Bloomington, Minn: Institute for Clinical Systems Improvement (ICSI). www.icsi.org/_asset/wjqy4g/HTN.pdf (2010, accessed 1 June 2017).

11.

James

Oparil

Carter

et al.

2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520.

12.

Wood S. JNC 8 at last! Guidelines ease up on BP thresholds, drug choices. Heartwire. www.medscape.com/viewarticle/817991 (2013, accessed 18 December 2013).

13.

Hajjar

anc Kotchen

. Trends in prevalence, awareness, treatment, and control of hypertension in the united states, 1988–2000. JAMA 2003; 290: 199–206.

14.

Sarah-Jo

Laurie

Adrian

et al.

Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysis. Eur J Prevent Cardiol 2016; 24: 228–238.

15.

Kornelia

Dirk

Guy

et al.

16.

van Vark

Bertrand

Akkerhuis

et al.

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088–2097.

17.

Baker

Coleman

Kluger

et al.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009; 151: 861–871.

18.

Hao

Wang

Guo

et al.

Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord 2014; 14: 148–148.

19.

Ong

. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol 2013; 151: 861–871.

20.

Ferrari

Boersma

. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther 2013; 11: 705–717.

21.

Higgins JPT and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011. Epub ahead of print 2011.

22.

Moher

Liberati

Tetzlaff

J AD

. PRISMA Group. Preferred reporting items for systematic reviews and meta analyses: The Prisma Statement. PLoS Med 2009; 6: 1–15.

23.

Mancia

Fagard

Narkiewicz

et al.

2013 ESH/ESC guidelines for the management of arterial hypertension (ESC). Eur Heart J 2013; 34: 2159–2219.

24.

Robinson

Dickersin

. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31: 150–153.

25.

ClinicalTrials.gov. Why should i register and submit results? www.clinicaltrials.gov/ct2/manage-recs/background (2011, accessed 25 August 2015).

26.

U.S. Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf (2007, accessed 30 May 2016).

27.

International Clinical Trials Registration Platform. International Standards for Clinical Trials Registries. http://apps.who.int/iris/bitstream/10665/76705/1/9789241504294_eng.pdf (2012, accessed 30 May 2016).

28.

Higgins JPTAD and Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011. http://training.cochrane.org/handbook (2011, accessed 2 May 2015).

29.

Hedges

Vevea

. Fixed- and random-effects models in meta-analysis. Psycholog Methods 1998; 3: 486–504.

30.

MacMahon

Sharpe

Gamble

et al.

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36: 438–443.

31.

Teo

Buller

Plante

et al.

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–1748.

32.

Yusuf

Sleight

Pogue

et al.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–153.

33.

Brenner

Cooper

de Zeeuw

et al.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

34.

Cohn

Tognoni

. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.

35.

Lewis

Hunsicker

Clarke

et al.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

36.

Pitt

O’Neill

Feldman

et al.

The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058–1063.

37.

Maggioni

Anand

Gottlieb

et al.

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414–1421.

38.

Fox

. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

39.

Lithell

Hansson

Skoog

et al.

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

40.

Remuzzi

. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117–3125.

41.

Suzuki

Kanno

. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. (E-COST) Group. Official journal of the Japanese Society of Hypertension 2005; 28: 307–314.

42.

Transcend Group Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–1183.

43.

Yusuf

Diener

H-C

Sacco

et al.

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–1237.

44.

Kasanuki

Hagiwara

Hosoda

et al.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–1212.

45.

Imai

Chan

JCN

Ito

et al.

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978–2986.

46.

Grassi

. The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. Expert Opin Pharmacother 2011; 12: 2421–2424.

47.

Bian

Kelton

CML

Guo

et al.

ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm 2010; 16: 671–679.

48.

Akobeng

. Principles of evidence based medicine. Arch Dis Child 2005; 90: 837–840.

49.

D’Agostino

Wolf

Belanger a

et al.

Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25: 40–43.

50.

Lindholm

Ibsen

Dahlöf

et al.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.

51.

Ferrario

. The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan. Curr Med Res Opin 2004; 20: 1797–1804.

52.

Lifton

Gharavi

Geller

. Molecular mechanisms of human hypertension. Cell 2001; 104: 545–556.

53.

Dendorfer

Wolfrum

Wagemann

et al.

Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 2001; 280: H2182–H2188.

54.

Dragović

Igić

Erdös

et al.

Metabolism of bradykinin by peptidases in the lung. Am Rev Respir Dis 1993; 147: 1491–1496.

55.

Brown

Ryder

Gainer

et al.

Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996; 279: 703–712.

56.

Beevers

Lip

O’Brien

. ABC of hypertension: the pathophysiology of hypertension. BMJ 2001; 322: 912–916.

57.

Camargo

ACM

Ianzer

Guerreiro

et al.

Bradykinin-potentiating peptides: beyond captopril. Toxicon 2012; 59: 516–523.

58.

Sharma

. Hypertension and the bradykinin system. Curr Hypertens Rep 2009; 11: 178–181.

59.

Hornig

Kohler

Drexler

. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115–1118.

60.

Bugge

Ytrehus

. Bradykinin protects against infarction but does not mediate ischemic preconditioning in the isolated rat heart. J Mol Cell Cardiol 1996; 28: 2333–2341.

61.

Cheng

Onishi

Ohte

et al.

Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 1998; 31: 1679–1686.

62.

Sigurdsson

Paulson

Hoj Nielsen

et al.

Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow. J Cereb Blood Flow Metab 2014; 34: 467–471.

63.

Kamiya

Katayama

Kashiwagi

et al.

The role of bradykinin in mediating ischemic brain edema in rats. Stroke 1993; 24: 571–576.

64.

Dell’Italia

Oparil

. Bradykinin in the Heart: Friend Or Foe? [Editorial]. Circulation 1999; 100: 2305–2307.

65.

van Wijngaarden

Tio

van Gilst

et al.

Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: prostaglandins and bradykinin. EurHeart J 1990; 11(Suppl B): 84–93.

66.

Ricciotti

Fitzgerald

. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986–1000.

67.

Wilson

. Renal prostaglandina synthesis and angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1992; 6: 39–44.

68.

Cosentino

Lüscher

. Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. Eur Heart J 1995; 16(Suppl K): 4–12.

69.

Bovenzi

Savard

Morin

et al.

Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J Cell Physiol 2010; 222: 168–176.

70.

Sasamura

Hayashi

Ishiguro

et al.

Prevention and regression of hypertension: role of renal microvascular protection. Hypertens Res 2009; 32: 658–664.

71.

Golias

Charalabopoulos

Stagikas

et al.

The kinin system – bradykinin: biological effects and clinical implications. Multiple role of the kinin system – bradykinin. Hippokratia 2007; 11: 124–128.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.46 MB